SLC5A2 and heart failure: Patients with heart failure are often managed by discontinuing osimertinib and with guideline-directed medical therapy, including renin-angiotensin system inhibition, beta-blockers, mineralocorticoid reception antagonists, and sodium-glucose cotransporter 2 inhibitors, as well as adjunctive therapies, such as loop diuretics (1).